Oxford University Clinical Research Unit, Vietnam

This phase 2 trial is testing two antivirals—molnupiravir (used for COVID-19) and a lab-made antibody called VIS513—in 500 people with early dengue. Participants must have had fever for less than 48 hours and a positive rapid test. The goal is to see if these drugs can clear the …